KRAS and non-small cell lung carcinoma: In addition, PD-L1 has not been associated with the major driver mutations in NSCLC (KRAS and EGFR) [106,107,108,109], questioning the clinical relevance of using PD1/PD-L1 blockers in NSCLC.